Capricor Therapeutics Files 8-K on Financials
Ticker: CAPR · Form: 8-K · Filed: Nov 13, 2024 · CIK: 1133869
| Field | Detail |
|---|---|
| Company | Capricor Therapeutics, Inc. (CAPR) |
| Form Type | 8-K |
| Filed Date | Nov 13, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, sec-filing
Related Tickers: CAPR
TL;DR
CAPR filed an 8-K on Nov 13, 2024, covering financial results. Details TBD.
AI Summary
On November 13, 2024, Capricor Therapeutics, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as well as financial statements and exhibits. No specific financial figures or operational updates were detailed in the provided excerpt.
Why It Matters
This filing indicates Capricor Therapeutics is providing updates on its financial status and operational results to the SEC, which is important for investors to monitor the company's performance.
Risk Assessment
Risk Level: low — This is a routine filing of financial information and does not inherently present new risks.
Key Players & Entities
- CAPRICOR THERAPEUTICS, INC. (company) — Registrant
- November 13, 2024 (date) — Date of Report
- 001-34058 (company) — SEC File Number
- Delaware (jurisdiction) — State of incorporation
FAQ
What specific financial results are being reported by Capricor Therapeutics?
The provided excerpt of the 8-K filing states that it concerns 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits,' but does not detail specific financial figures.
When was this 8-K report filed with the SEC?
The report was filed on November 13, 2024.
What is the SEC file number for Capricor Therapeutics?
Capricor Therapeutics' SEC file number is 001-34058.
In which state is Capricor Therapeutics incorporated?
Capricor Therapeutics, Inc. is incorporated in Delaware.
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on Capricor Therapeutics, Inc.'s results of operations and financial condition, along with financial statements and exhibits.
Filing Stats: 531 words · 2 min read · ~2 pages · Grade level 10.2 · Accepted 2024-11-13 16:02:22
Key Financial Figures
- $0.001 — h Registered Common Stock, par value $0.001 per share CAPR The Nasdaq Capital M
Filing Documents
- capr-20241113x8k.htm (8-K) — 38KB
- capr-20241113xex99d1.htm (EX-99.1) — 163KB
- capr-20241113xex99d1001.jpg (GRAPHIC) — 5KB
- 0001558370-24-015519.txt ( ) — 337KB
- capr-20241113.xsd (EX-101.SCH) — 3KB
- capr-20241113_lab.xml (EX-101.LAB) — 15KB
- capr-20241113_pre.xml (EX-101.PRE) — 9KB
- capr-20241113x8k_htm.xml (XML) — 5KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On November 13, 2024, Capricor Therapeutics, Inc., a Delaware corporation (the "Company"), issued a press release announcing its financial results for the quarter ended September 30, 2024. A copy of the press release is being furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K. The information under Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto is being furnished and shall not be deemed to be filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be incorporated by reference into any of the Company's filings under the Exchange Act, unless expressly set forth as being incorporated by reference into such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits 99.1 Press Release, titled "Capricor Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update", dated November 13, 2024. 104 Cover Page Interactive Data File (formatted as inline XBRL). 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized. CAPRICOR THERAPEUTICS, INC. Date: November 13, 2024 By: /s/ Linda Marbn, Ph.D. Linda Marbn, Ph.D. Chief Executive Officer 3